Viatris、Teva在Oppenheimer的Outperform上发起

2026-09-24 00:12

Oppenheimer began coverage of Viatris (VTRS) and Teva Pharmaceutical Industries (TEVA) with Outperform ratings for both.
The price target for Viatris is $25 (~46% upside based on Sept. 22 close), while for Teva, it is $50 (~27% upside).
Analyst Les Sulewski said that Teva is benefitting from "a combination of improving fundamentals and largely unpriced pipeline optionality," adding that the "market continues to value VTRS as a declining generics and established-brands company, overlooking an improving base business, cost savings, and a late-stage pipeline."
One of Viatris' most eagerly anticipated pipeline assets is cenerimod for systemic lupus erythematosus and lupus nephritis. A readout of phase 3 data for SLE is expected by the end of the year, while enrollment in a phase 3 trial for lupus nephritis is expected to complete in H1 2028.
As Teva is entering a period of transformation, Sulewski sees "meaningful earnings upside potential." He added that "investors remain overly focused on Austedo's 2027 Medicare price reset and gRevlimid erosion, while assigning insufficient value to Teva’s commercial execution, emerging neuroscience franchise, and immunology platforms."

More on Viatris